A

Arvinas
D

ARVN

17.750
USD
-0.60
(-3.27%)
مغلق
حجم التداول
63,057
الربح لكل سهم
-2
العائد الربحي
-
P/E
-6
حجم السوق
1,220,700,639
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALLO
    -0.07500
    (-3.33%)
    2.17500 USD
    B
    BEAM
    -2.705
    (-8.16%)
    30.445 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    MRNA
    MRNA
    1.785
    (5.29%)
    35.535 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    T
    TXG
    -0.680
    (-5.88%)
    10.880 USD
    V
    VYGR
    -0.04000
    (-0.94%)
    4.22500 USD
    المزيد
الأخبار
المقالات

العنوان: Arvinas

القطاع: Healthcare
الصناعة: Biotechnology
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.